Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | EVP, PRESIDENT, DRUG DELIVERY | June 30, 2026 | July 02, 2026 |
| Savara IncSVRA · Entity 4900 | Director | December 19, 2025 | December 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HALOZYME THERAPEUTICS, INC.
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,592 |
Ending reported balance
After 2026-06-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-30 · Exercise / conversion · Acquired 10,000 · Balance 10,000 Row 2 · 2026-06-30 · Tax withholding · Disposed 5,408 · Balance 4,592 F1: The reported disposition of 5,408 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-06-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-30 · Exercise / conversion · Disposed 10,000 · Balance 0 F2: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. The shares received upon vesting remain subject to a one-year holding period from the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 16,232 |
Reported balance
After 2026-07-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-01 · Grant · Acquired 16,232 · Balance 16,232 F3: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $77.01 · Expires 2036-07-01 | Direct | 39,823 |
Reported balance
After 2026-07-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-01 · Grant · Acquired 39,823 · Balance 39,823 F4: This option vests one-fourth on such date and then 1/48th monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported disposition of 5,408 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
F2: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. The shares received upon vesting remain subject to a one-year holding period from the vesting date.
F3: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.
F4: This option vests one-fourth on such date and then 1/48th monthly thereafter.
Savara Inc
Report date December 19, 2025 · Filed December 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,533,642 |
Reported balance
After 2025-12-19 transaction · row 1
1 source rowRow 1 · 2025-12-19 · Sale · Disposed 20,000 · Balance 2,533,642 F1: Represents shares sold to satisfy tax liability upon the vesting of restricted stock units. F2: The price is a weighted average sales price. The sale prices ranged from $6.04 to $6.08. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold to satisfy tax liability upon the vesting of restricted stock units.
F2: The price is a weighted average sales price. The sale prices ranged from $6.04 to $6.08. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LA JOLLA PHARMACEUTICAL CO
Report date August 22, 2022 · Filed August 24, 2022
Section 16 reporting ended · disclosed 2022-08-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 1
1 source rowRow 1 · 2022-08-22 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.43 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-08-22 · Disposition to issuer · Disposed 18,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.93 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-08-22 · Disposition to issuer · Disposed 12,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.81 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-08-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $4.53 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-08-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 12, 2022 Filed Jan 14, 2022 21:00 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $4.81 | $0.00 |
DisclosureSEC source: 0001209191-22-003405 · doc4.xml · derivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-01-12 F1 · derivative.exercise_date: The stock options vest and become exercisable on January 12, 2023 subject to the Reporting Person's continued service to the Issuer through such date. Read SEC document |
| December 30, 2021 Filed Dec 30, 2021 19:00 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 35,000 | $1.30 | $45,360.00 |
DisclosureSEC source: 0001209191-21-071589 · doc4.xml · nonDerivative · entry 2 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,501,142 F2 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.29 to $1.30. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| December 29, 2021 Filed Dec 30, 2021 19:00 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 15,000 | $1.25 | $18,675.00 |
DisclosureSEC source: 0001209191-21-071589 · doc4.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,466,142 F1 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.24 to $1.25. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| December 17, 2021 Filed Dec 17, 2021 17:29 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 25,000 | $1.13 | $28,225.00 |
DisclosureSEC source: 0001209191-21-070142 · doc4.xml · nonDerivative · entry 2 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,451,142 F2 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.125 to $1.13. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 17:29 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 15,000 | $1.08 | $16,260.00 |
DisclosureSEC source: 0001209191-21-070142 · doc4.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,426,142 F1 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.07 to $1.10. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| December 14, 2021 Filed Dec 14, 2021 23:31 UTC | Savara Inc SVRA · Entity 4900 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001209191-21-069587 · doc4.xml · derivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-12-14 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable on December 14, 2022. Read SEC document |
| December 10, 2021 Filed Dec 13, 2021 19:05 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 35,000 | $1.04 | $36,365.00 |
DisclosureSEC source: 0001209191-21-069189 · doc4.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,411,142 F1 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.03 to $1.04. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| December 08, 2021 Filed Dec 9, 2021 17:12 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 13,157 | $1.05 | $13,814.85 |
DisclosureSEC source: 0001209191-21-068660 · doc4.xml · nonDerivative · entry 2 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,376,142 Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 17:12 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 11,843 | $1.05 | $12,399.62 |
DisclosureSEC source: 0001209191-21-068660 · doc4.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,362,985 F1 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.04 to $1.05. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| December 06, 2021 Filed Dec 6, 2021 21:01 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 3,000 | $3.87 | $11,610.00 |
DisclosureSEC source: 0001209191-21-068221 · doc4.xml · nonDerivative · entry 18 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Read SEC document |
| December 06, 2021 Filed Dec 6, 2021 21:01 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 1,000 | $3.84 | $3,840.00 |
DisclosureSEC source: 0001209191-21-068221 · doc4.xml · nonDerivative · entry 17 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,000 Read SEC document |
| December 06, 2021 Filed Dec 6, 2021 21:01 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 2,215 | $3.82 | $8,461.30 |
DisclosureSEC source: 0001209191-21-068221 · doc4.xml · nonDerivative · entry 16 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,000 Read SEC document |
| December 06, 2021 Filed Dec 6, 2021 21:01 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 1,000 | $3.81 | $3,810.00 |
DisclosureSEC source: 0001209191-21-068221 · doc4.xml · nonDerivative · entry 15 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,785 Read SEC document |
| December 06, 2021 Filed Dec 6, 2021 21:01 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 1,000 | $3.80 | $3,800.00 |
DisclosureSEC source: 0001209191-21-068221 · doc4.xml · nonDerivative · entry 14 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,785 Read SEC document |
| December 06, 2021 Filed Dec 6, 2021 21:01 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 785 | $3.77 | $2,959.45 |
DisclosureSEC source: 0001209191-21-068221 · doc4.xml · nonDerivative · entry 13 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,785 Read SEC document |
| December 06, 2021 Filed Dec 6, 2021 21:01 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 1,000 | $3.75 | $3,750.00 |
DisclosureSEC source: 0001209191-21-068221 · doc4.xml · nonDerivative · entry 12 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,000 Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 21:01 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 1,000 | $3.69 | $3,690.00 |
DisclosureSEC source: 0001209191-21-068221 · doc4.xml · nonDerivative · entry 11 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 21:01 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 1,000 | $3.68 | $3,680.00 |
DisclosureSEC source: 0001209191-21-068221 · doc4.xml · nonDerivative · entry 10 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,000 Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 21:01 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 399 | $3.64 | $1,452.36 |
DisclosureSEC source: 0001209191-21-068221 · doc4.xml · nonDerivative · entry 9 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,000 Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 21:01 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 2,000 | $3.63 | $7,260.00 |
DisclosureSEC source: 0001209191-21-068221 · doc4.xml · nonDerivative · entry 8 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,601 Read SEC document |
| December 02, 2021 Filed Dec 2, 2021 17:48 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 21,394 | $1.09 | $23,233.88 |
DisclosureSEC source: 0001209191-21-067437 · doc4.xml · nonDerivative · entry 2 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,351,142 F1 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.08 to $1.09. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 21:01 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 1,000 | $3.80 | $3,800.00 |
DisclosureSEC source: 0001209191-21-068221 · doc4.xml · nonDerivative · entry 7 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,601 Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 21:01 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 1,000 | $3.78 | $3,780.00 |
DisclosureSEC source: 0001209191-21-068221 · doc4.xml · nonDerivative · entry 6 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,601 Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 21:01 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 2,400 | $3.74 | $8,976.00 |
DisclosureSEC source: 0001209191-21-068221 · doc4.xml · nonDerivative · entry 5 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,601 Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 21:01 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 1,100 | $3.73 | $4,103.00 |
DisclosureSEC source: 0001209191-21-068221 · doc4.xml · nonDerivative · entry 4 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,201 Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 21:01 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 1,000 | $3.71 | $3,710.00 |
DisclosureSEC source: 0001209191-21-068221 · doc4.xml · nonDerivative · entry 3 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,101 Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 21:01 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 2,000 | $3.70 | $7,400.00 |
DisclosureSEC source: 0001209191-21-068221 · doc4.xml · nonDerivative · entry 2 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,101 Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 21:01 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 1,601 | $3.69 | $5,907.69 |
DisclosureSEC source: 0001209191-21-068221 · doc4.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,101 Read SEC document |
| December 01, 2021 Filed Dec 1, 2021 18:15 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 9,000 | $1.09 | $9,765.00 |
DisclosureSEC source: 0001209191-21-067244 · doc4.xml · nonDerivative · entry 2 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,326,142 F2 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.08 to $1.105. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 17:48 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 3,606 | $1.08 | $3,894.48 |
DisclosureSEC source: 0001209191-21-067437 · doc4.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,329,748 Read SEC document |
| November 30, 2021 Filed Dec 1, 2021 18:15 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 16,000 | $1.09 | $17,392.00 |
DisclosureSEC source: 0001209191-21-067244 · doc4.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,317,142 F1 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.08 to $1.10. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| November 22, 2021 Filed Nov 22, 2021 16:43 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 90,000 | $1.08 | $97,020.00 |
DisclosureSEC source: 0001209191-21-066037 · doc4.xml · nonDerivative · entry 3 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,301,142 F3 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.06 to $1.09. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 16:43 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 49,800 | $1.07 | $53,236.20 |
DisclosureSEC source: 0001209191-21-066037 · doc4.xml · nonDerivative · entry 2 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,211,142 F2 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.06 to $1.08. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 16:43 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 60,200 | $1.08 | $65,136.40 |
DisclosureSEC source: 0001209191-21-066037 · doc4.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,161,342 F1 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.06 to $1.10. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 17:05 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 7,500 | $4.23 | $31,725.00 |
DisclosureSEC source: 0001209191-21-065859 · doc4.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,500 Read SEC document |
| September 30, 2021 Filed Sep 30, 2021 16:37 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 50,000 | $1.30 | $64,900.00 |
DisclosureSEC source: 0001209191-21-058141 · doc4.xml · nonDerivative · entry 3 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,101,142 F3 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.27 to $1.32. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| September 29, 2021 Filed Sep 30, 2021 16:37 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 47,500 | $1.28 | $60,657.50 |
DisclosureSEC source: 0001209191-21-058141 · doc4.xml · nonDerivative · entry 2 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,051,142 F2 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.26 to $1.29. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| September 28, 2021 Filed Sep 30, 2021 16:37 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 39,552 | $1.29 | $50,824.32 |
DisclosureSEC source: 0001209191-21-058141 · doc4.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,003,642 F1 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.27 to $1.29. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 00:12 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 17,788 | $1.22 | $21,701.36 |
DisclosureSEC source: 0001209191-21-052653 · doc4.xml · nonDerivative · entry 3 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 964,090 Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 00:12 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 12,948 | $1.18 | $15,278.64 |
DisclosureSEC source: 0001209191-21-052653 · doc4.xml · nonDerivative · entry 2 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 946,302 Read SEC document |
| August 17, 2021 Filed Aug 20, 2021 00:12 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 66,554 | $1.18 | $78,200.95 |
DisclosureSEC source: 0001209191-21-052653 · doc4.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 933,354 F1 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.17 to $1.18. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| May 24, 2021 Filed May 26, 2021 18:28 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 600 | $3.60 | $2,160.00 |
DisclosureSEC source: 0001209191-21-036024 · doc4.xml · nonDerivative · entry 12 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,000 Read SEC document |
| May 24, 2021 Filed May 26, 2021 18:28 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 400 | $3.57 | $1,428.00 |
DisclosureSEC source: 0001209191-21-036024 · doc4.xml · nonDerivative · entry 11 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,400 Read SEC document |
| May 24, 2021 Filed May 26, 2021 18:28 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 1,000 | $3.54 | $3,540.00 |
DisclosureSEC source: 0001209191-21-036024 · doc4.xml · nonDerivative · entry 10 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 Read SEC document |
| May 24, 2021 Filed May 26, 2021 18:28 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 1,000 | $3.53 | $3,530.00 |
DisclosureSEC source: 0001209191-21-036024 · doc4.xml · nonDerivative · entry 9 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,000 Read SEC document |
| May 24, 2021 Filed May 26, 2021 18:28 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 2,000 | $3.52 | $7,040.00 |
DisclosureSEC source: 0001209191-21-036024 · doc4.xml · nonDerivative · entry 8 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Read SEC document |
| May 24, 2021 Filed May 26, 2021 18:28 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 1,000 | $3.51 | $3,510.00 |
DisclosureSEC source: 0001209191-21-036024 · doc4.xml · nonDerivative · entry 7 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,000 Read SEC document |
| May 24, 2021 Filed May 26, 2021 18:28 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 3,000 | $3.50 | $10,500.00 |
DisclosureSEC source: 0001209191-21-036024 · doc4.xml · nonDerivative · entry 6 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 Read SEC document |
| May 24, 2021 Filed May 26, 2021 18:28 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 2,000 | $3.49 | $6,980.00 |
DisclosureSEC source: 0001209191-21-036024 · doc4.xml · nonDerivative · entry 5 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Read SEC document |
| May 24, 2021 Filed May 26, 2021 18:28 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 4,000 | $3.48 | $13,920.00 |
DisclosureSEC source: 0001209191-21-036024 · doc4.xml · nonDerivative · entry 4 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.